Technologies

The technology, developed by CNR-ICB, is based on an innovative bioprocess called "Caphnophilic (CO2-requiring) Lactic Fermentation (CLF)”, developed in the hyperthermophilic bacterium Thermotoga neapolitana (EP patent: EP2948556B1), which allows the production of "green" hydrogen and capture and valorization of CO2 in L -lactic acid (98% e.e.).

Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.

The  invention relates to the water purification sector; it refers to a phytodepuration module and to a plant including this module. The objective is decontamination and recovery of drinking water from contaminated springs and wells, thermal, rainwater, wastewater and industrial wastewater. Phytodepuration tanks are known which use ferns to decontaminate water, but have the limits of requiring large surfaces and / or long treatment times.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.